In a retrospective analysis, investigators assessed the effects of topical trigger point treatments on headache symptoms in patients with migraine.
Approximately half of patients with migraine have kinesiophobia, and the condition is associated with greater severity, not presence of cutaneous allodynia.
Researchers showed high migraine induction capabilities with calcitonin gene-related peptide (CGRP) in people with migraine who responded to erenumab treatment compared to data from previous CGRP provocation experiments.
Higher levels of serum 25-hydroxyvitamin D may be associated with lower risk for migraine headaches.
Migraine may be associated with self-reported attention deficit and hyperactivity disorder symptoms in university students.
Erenumab 140 mg is a well-tolerated and potentially effective preventive treatment for patients with episodic migraine, according to a phase 3b study.
There is significant evidence that opioids are not the right treatment of choice for migraine in the emergency department.
Genetic risk scores that focus on 2 single-nucleotide polymorphisms associated with migraines without aura might help predict patient response to triptan treatment.
Study showed no evidence for an effect of achievement motivation on the frequency of acute headache medication use.
There is a need for a tool in primary care to aid in managing and diagnosing headache disorders.
Counseling practices and headache management indicate the need for training and education of pharmacists in an Ethiopian city to better serve individuals with headache complaints.
Improved pain acceptance may be associated with a decrease in headache-related disability in patients with migraine.
A study looked at use of IV fluids, ketorolac, dexamethasone, and DRAs prochlorperazine/metoclopramide from 1999-2000 to 2014 in the treatment of patients with migraine admitted to the ED.
The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.
Distinct response patterns of the 22-item Sino-Nasal Outcome Test may be used to distinguish nonsinogenic headaches from chronic rhinosinusitis.
Investigators examined the link between migraine and attention-deficit/hyperactivity disorder.
Investigators examined opioid prescribing trends in children and adolescents with primary headaches during ambulatory and emergency department visits.
The continued observation of this delayed headache syndrome may point to a different pathophysiology from tension-type headache or acute poststroke headache.
The authors built a customized structured clinical documentation support toolkit that collects hundreds of fields of discrete, standardized data.
Investigators identify subgroups of individuals with migraine based on comorbidities and concomitant condition.
Investigators aim to develop a non-invasive treatment for medically refractory chronic migraine not requiring a permanent implant.
Many headache smartphone applications or "apps" share information with third parties, more than half of which have privacy policies stating that the shared data will be used to serve targeted advertisements from third parties.
Investigators examine most bothersome headache-associated symptoms as a feasible alternative to using 4 c-primary end points in acute migraine treatment trials.
Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.
The Sapphire has a rechargeable and reloadable fill capacity; it can be activated monthly by inputting a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed to the patient.
Investigators examined rates, predictors, and outcomes of neuroimaging in pediatric and adolescent patients who presented to the ED with a headache.
Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.
Investigators assessed the effect of erenumab on total exercise time, time to exercise-induced angina, and ST depression in patients with stable angina.
No significant clinical differences have been found between individuals with cluster headache who experience aura vs no aura.
People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Opioids: Clinician Concern and Prescribing Practices
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- CDC: 8.8% of Individuals in the United States Uninsured in First Half of 2018
- Patient Experiences Shed Light on Diagnostic Errors
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Wikipedia in Medical Education: An Educator's Guide to Crowdsourcing